On this page
What Is a Gastrinoma?
A gastrinoma is a type of neuroendocrine tumor that arises from gastrin-secreting cells (also called G-cells). Gastrin is a hormone whose primary physiological role is to stimulate the stomach to produce gastric acid (hydrochloric acid), which is essential for digestion.
Gastrinomas are most commonly found in the duodenum (the first segment of the small intestine) or the pancreas.
By definition, a tumor is an uncontrolled proliferation of cells, so the consequences of a gastrinoma follow a predictable pathological cascade:
- Increased number of gastrin-producing cells: unregulated gastrin secretion
- Markedly elevated gastrin levels in the bloodstream (hypergastrinemia)
- Excessive gastric acid production (hypersecretion)
- Acid-induced damage to the stomach and duodenal lining: leads to the formation of peptic ulcers and chronic diarrhea
This characteristic combination of findings (peptic ulceration, gastric acid hypersecretion, and a gastrin-secreting tumor) is recognized as a distinct clinical syndrome known as Zollinger-Ellison Syndrome (ZES).
Gastrinomas most frequently develop in the pancreas, where they represent the most common type of malignant endocrine tumor. Unfortunately, the prognosis is often serious: at least 60% of gastrinomas have already metastasized at the time of diagnosis, significantly limiting treatment options and worsening outcomes.
Causes
As with most cancers, the precise triggering cause of a gastrinoma cannot be identified in the majority of cases. Neither pancreatic neuroendocrine tumors in general, nor gastrinomas specifically, are exceptions to this rule.
Genetic Predisposition: MEN1 Syndrome
In approximately 2–3 out of every 10 patients, a hereditary predisposition is identified. The most important genetic risk factor is Multiple Endocrine Neoplasia type 1 (MEN1), an autosomal dominant syndrome caused by mutations in the MEN1 gene on chromosome 11. Patients with MEN1 are predisposed to developing tumors of the parathyroid glands, anterior pituitary, and pancreatic islet cells (including gastrinomas).
Epidemiology
- Global incidence is estimated at 0.5–3 cases per million people per year, making gastrinoma a rare but clinically important condition
- It is most commonly diagnosed between the ages of 20 and 50, with a slightly higher incidence in men
- In patients with MEN1, gastrinomas tend to present earlier, typically between ages 10 and 30
Anatomical Location: The “Gastrinoma Triangle”
Gastrin-secreting cells are distributed across multiple organs, so gastrinomas can theoretically arise in various locations. However, the vast majority occur within a well-defined anatomical region of the abdomen known as the “gastrinoma triangle”, bounded by:
- The junction of the cystic and common bile ducts (superiorly)
- The junction of the second and third portions of the duodenum (inferiorly)
- The neck and body of the pancreas (medially)
Rare but documented extrapancreatic sites include:
- Stomach
- Peripancreatic lymph nodes
- Liver
- Bile duct
- Ovaries
- Heart
- In association with small cell lung carcinoma
Symptoms
The symptoms of gastrinoma are directly attributable to the pathological effects of excess gastrin and gastric acid hypersecretion.
Mechanism of Symptom Development
-
Peptic ulcer formation: Chronically elevated gastric acid gradually overwhelms the protective mucosal defenses of the stomach and duodenum, causing painful ulcerations. These ulcers are often multiple, located in atypical positions (e.g., distal duodenum or jejunum), and frequently refractory to standard ulcer therapy, a key clinical red flag for gastrinoma.
-
Diarrhea and malabsorption: Excess acid entering the small intestine inactivates pancreatic digestive enzymes and damages the intestinal mucosa, impairing nutrient absorption. Fat malabsorption leads to steatorrhea (greasy, malodorous stools), which is characteristic.
Most Common Clinical Manifestations
- Abdominal pain: The most frequent presenting complaint, typically epigastric and often related to peptic ulceration
- Chronic diarrhea: Present in up to 70–75% of patients; may precede the diagnosis by months or years
Additional Symptoms
- Dyspepsia (indigestion, bloating, early satiety)
- Gastroesophageal reflux (GERD): Due to acid overflow into the esophagus
- Gastrointestinal bleeding: From ulcer erosion into blood vessels
- Unintentional weight loss: Due to malabsorption and decreased appetite from pain
- Nausea and vomiting
Clinical Alert: The presence of multiple peptic ulcers, ulcers in unusual locations (distal duodenum, jejunum), or ulcers that fail to respond to standard proton pump inhibitor (PPI) therapy should always prompt evaluation for gastrinoma and Zollinger-Ellison Syndrome.
Survival, Prognosis, and Disease Course
Gastrinomas are generally slow-growing tumors, but their clinical course is highly variable and primarily determined by the presence or absence of metastatic disease, particularly liver metastases.
Key prognostic facts:
- Approximately 60% of gastrinomas are malignant and have already spread to distant sites (most commonly the liver) at the time of diagnosis
- Liver metastases are the single most important determinant of survival
Survival Rates by Disease Stage
| Disease Stage | 5-Year Survival | 10-Year Survival |
|---|---|---|
| Localized (no liver metastases) | ~95% | ~90% or more |
| Metastatic (liver involvement) | ~50% | ~30% |
These figures highlight the critical importance of early diagnosis before metastatic spread, as surgical cure is possible in a substantial proportion of patients with localized disease.
Prognostic Factors
Factors associated with a poorer prognosis include:
- Presence of liver metastases at diagnosis
- Large primary tumor size (> 3 cm)
- Primary pancreatic location (vs. duodenal)
- High tumor grade (Ki-67 proliferation index)
- Association with sporadic disease (as opposed to MEN1-associated gastrinomas, which tend to behave less aggressively)
Diagnosis
Suspicion for gastrinoma typically arises when a patient presents with peptic ulcers (gastric and/or duodenal) combined with chronic diarrhea, particularly when ulcers are multiple, atypically located, or unresponsive to standard treatment.
Biochemical Tests
- Fasting serum gastrin level: The cornerstone of biochemical diagnosis. Gastrin levels are markedly elevated in gastrinoma (typically > 10 times the upper limit of normal). The test must be performed after withholding proton pump inhibitors for at least 1–2 weeks, as PPIs themselves can raise gastrin levels.
- Secretin stimulation test: When fasting gastrin levels are borderline elevated (100–1000 pg/mL), an intravenous secretin injection is administered. In patients with gastrinoma, serum gastrin levels paradoxically increase by ≥ 200 pg/mL, a highly specific diagnostic response.
- Chromogranin A (CgA): A non-specific neuroendocrine tumor marker measured in the blood. While not diagnostic of gastrinoma specifically, CgA levels correlate with tumor volume and are useful for monitoring disease progression and response to therapy.
- Gastric acid output measurement: Basal acid output (BAO) > 15 mEq/hour (or > 5 mEq/hour in previously operated patients) is highly suggestive of Zollinger-Ellison Syndrome.
Imaging Studies
Accurate tumor localization is essential for surgical planning:
- Magnetic Resonance Imaging (MRI): Generally more informative than CT for soft tissue characterization; preferred for evaluating liver metastases and pancreatic lesions
- CT scan (computed tomography): Widely used for initial staging; detects larger tumors and distant metastases
- Somatostatin receptor scintigraphy (Octreoscan) / Gallium-68 DOTATATE PET/CT: Highly sensitive functional imaging that exploits the overexpression of somatostatin receptors on gastrinoma cells; currently considered the most sensitive imaging modality for detecting primary tumors and metastases, including small duodenal lesions missed by conventional imaging
- Endoscopic Ultrasound (EUS): Combines endoscopy with real-time ultrasound guidance; particularly valuable for identifying small pancreatic and duodenal tumors not visible on cross-sectional imaging, and allows guided biopsy for histological confirmation
- Upper GI endoscopy (gastroscopy): Directly visualizes and documents peptic ulcers and mucosal changes consistent with acid hypersecretion
In selected cases where all other modalities fail to localize the tumor, exploratory laparotomy (traditional open surgical exploration) may be necessary to identify the tumor site.
Treatment
Surgery: The Treatment of Choice
Surgical resection is the only potentially curative treatment for gastrinoma and remains the preferred approach when feasible. Successful complete resection can achieve long-term remission and significantly improve survival.
However, surgery is not always possible in the following situations:
- Multiple tumors (especially in MEN1 patients, who commonly develop multifocal disease)
- Anomalous or inaccessible tumor location
- Metastatic disease, particularly extensive liver involvement
Medical Management: Symptom Control
Regardless of tumor resectability, symptom relief and prevention of peptic ulcer complications are paramount for virtually all patients:
- High-dose Proton Pump Inhibitors (PPIs) (e.g., omeprazole, pantoprazole, esomeprazole): The medical treatment of choice for controlling gastric acid hypersecretion. High doses are typically required and have demonstrated excellent efficacy in reducing symptoms and preventing ulcer complications. PPIs have revolutionized the management of Zollinger-Ellison Syndrome and significantly improved quality of life.
Hormone Therapy: Somatostatin Analogues
- Octreotide and lanreotide (synthetic analogues of the hormone somatostatin) effectively reduce gastric acid secretion by inhibiting gastrin release. They also appear to slow tumor growth in some cases and represent important tools for symptom management, particularly in metastatic disease.
- However, somatostatin analogues have limited direct antitumor activity and do not substitute for surgery or oncological therapy.
Treatment of Metastatic Disease
For patients with unresectable or metastatic gastrinoma, current treatment options include:
- Chemotherapy: Combinations such as streptozocin + doxorubicin or temozolomide-based regimens; overall efficacy is limited, with modest response rates
- Peptide receptor radionuclide therapy (PRRT): A targeted approach using radiolabeled somatostatin analogues (e.g., Lutetium-177 DOTATATE / Lutathera®) to deliver radiation directly to somatostatin receptor-expressing tumor cells; shown to improve progression-free survival in advanced NETs
- Liver-directed therapies: For patients with predominantly hepatic metastases, options include hepatic artery embolization, chemoembolization (TACE), or radiofrequency ablation
- Targeted therapies: Including everolimus (mTOR inhibitor), which has demonstrated efficacy in advanced pancreatic NETs
Note: Radiotherapy is not generally recommended for gastrinomas, as these tumors show limited radiosensitivity.
Emerging and Investigational Approaches
Several promising therapeutic strategies are under active clinical investigation:
- Anti-angiogenic therapies: Targeting tumor blood vessel formation (e.g., sunitinib, bevacizumab)
- mTOR pathway inhibition: Further refinement of everolimus-based protocols
- Combination PRRT regimens: Optimizing radionuclide therapy combinations
- Immunotherapy: Checkpoint inhibitors are being studied in poorly differentiated neuroendocrine carcinomas
These approaches await broader clinical validation and large-scale implementation, but represent an exciting frontier in the management of advanced gastrinoma.
Sources and Bibliography
- Cingam SR, Botejue M, Hoilat GJ, Karanchi H. Gastrinoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK441842/
- Osmosis. Gastrinoma (Zollinger-Ellison Syndrome). https://www.osmosis.org/answers/gastrinoma
- Cancer Research UK. Gastrinoma Survival Statistics. https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets/pancreatic-nets/gastrinoma/survival
- Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes. Neuroendocrinology. 2012;95(2):98-119. https://doi.org/10.1159/000335591
- Ito T, Igarashi H, Jensen RT. Zollinger-Ellison Syndrome: Recent Advances and Controversies. Current Opinion in Gastroenterology. 2013;29(6):650-661.
- Strosberg J, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1). New England Journal of Medicine. 2017;376:125-135. https://doi.org/10.1056/NEJMoa1607427
- Yao JC, et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors (RADIANT-3). New England Journal of Medicine. 2011;364:514-523. https://doi.org/10.1056/NEJMoa1009290
- National Cancer Institute (NCI). Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®). https://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq
- Kasper DL, Fauci AS, et al. Harrison’s Principles of Internal Medicine, 21st Edition. McGraw-Hill Education, 2022.
